ArticleJournal of applied toxicology : JAT2021
Toxicological safety evaluation of pasteurized Akkermansia muciniphila.
Article in Journal of applied toxicology : JAT, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05738746 (The Effects of the Anti-inflammatory Microbe - Pasteurized Akkermansia Muciniphila), which is not on this map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Effects of the Anti-inflammatory Microbe - Pasteurized Akkermansia Muciniphila (PAM) on Symptoms of Somatic and Mental Stress in Healthcare Professionals
Who cites it
35 citing papers in PubMed.
- Trial
- Synergistic Anti-Obesity Effect ofFood science & nutrition · 2026Article
- Akkermansia muciniphila : A next-generation gut probiotic supporting neurorepair and functional recovery.Neural regeneration research · 2026Article
- Translational human gut microbiome research: What are the missing pieces of the puzzle?Journal of translational medicine · 2026Review
- High stability of the genome ofMicrobiology spectrum · 2026Article
- Postbiotics: Definitions, Manufacturing, Analytical Characterization, and Clinical Evidence for Human and Animal Health.Current microbiology · 2026Review
- Dual functional properties of a probiotic biofilm-decorated bone substitute to combat infection and promote osteoimmunomodulation.Bioactive materials · 2026Article
- Demystifying the role of postbiotics in inflammation mediated metabolic disorders: an updated review.Food science and biotechnology · 2026Review
- PasteurizedFrontiers in pharmacology · 2026Review
- Strain-Specific Safety Evaluation ofFood science & nutrition · 2025Article
- Safety evaluation ofToxicology reports · 2025Article
- The role ofiMetaOmics · 2025Article
- Article
- Probiotic attributes and safety profile of AKM Lab-01: a novelFrontiers in microbiology · 2025Article
- Review
- Review
- Lack of genotoxicity and subchronic toxicity in safety assessment studies ofToxicology reports · 2024Article
- Biotics and bacterial function: impact on gut and host health.The ISME journal · 2024Review
- Omics-based analysis ofMicrobiome research reports · 2024Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gut microorganisms are vital for many aspects of human health, and the commensal bacterium Akkermansia muciniphila has repeatedly been identified as a key component of intestinal microbiota. Reductions in A. muciniphila abundance are associated with increased prevalence of metabolic disorders such as obesity and type 2 diabetes. It was recently discovered that administration of A. muciniphila has beneficial effects and that these are not diminished, but rather enhanced after pasteurization. Pasteurized A. muciniphila is proposed for use as a food ingredient, and was therefore subjected to a nonclinical safety assessment, comprising genotoxicity assays (bacterial reverse mutation and in vitro mammalian cell micronucleus tests) and a 90-day toxicity study. For the latter, Han Wistar rats were administered with the vehicle or pasteurized A. muciniphila at doses of 75, 375 or 1500 mg/kg body weight/day (equivalent to 4.8 × 10
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.